Content area

|
|

Immunterapi med checkpointhæmmere og endokrinologiske bivirkninger

Forfattere
Line Bisgaard Jørgensen1, Lars Bastholt2 & Knud Yderstræde1 1) Endokrinologisk Afdeling, Odense Universitetshospital 2) Onkologisk Afdeling, Odense Universitets-hospital Ugeskr Læger 2017;179:V05170362
Reference: 
Ugeskr Læger 2017;179:V05170362
Blad nummer: 
Sidetal: 
2-6
Immune checkpoint inhibitors and endocrinological side effects
Immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte-associated antigen-4 and anti-programmed cell death-1 have revolutionized cancer therapy but have also induced serious immune-related adverse events including hormonal dysfunction. The objective of this review is to characterize the incidence, clinical presentation, management and prognosis of the endocrine-related adverse events including hypophysitis, thyroid dysfunction and diabetes mellitus. Combination therapy is associated with an increased risk of adverse events. We recommend close monitoring of the hormone levels and glycaemic status during and a year after treatment.

💬 0 Kommentarer

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Stine Bjerrum Runge | 22/06
2 kommentarer
af Preben Joffe | 22/06
1 Kommentar
af Charlotte Schulsinger | 22/06
6 kommentarer
af Jens-Jørgen Gravesen | 20/06
1 Kommentar
af Tata Marion Ringberg | 18/06
4 kommentarer
af Michael Lee Heyman | 18/06
2 kommentarer
af Gitte E. Egsdal Wienholtz | 18/06
3 kommentarer
af Finn Olav Hansen | 17/06
2 kommentarer